AMSTERDAM, Netherlands — November 27, 2025. Arletta Pharma Solutions, formerly known as Freya Pharma Solutions, has unveiled a major corporate rebranding as it enters the final stage of clinical development for its flagship therapy Lybrido™, aimed at treating Female Sexual Interest/Arousal Disorder (FSIAD) and Hypoactive Sexual Desire Disorder (HSDD). The new identity—symbolized by a rare butterfly species—reflects the company’s scientific evolution, strengthened clinical pipeline and advancing path toward regulatory submission. This milestone is supported by the ongoing Clitoral Doppler Duplex Ultrasonography (CDU) Phase II study, near-term data expectations, and preparations for the pivotal ALETTA Phase III-intended study pending financing completion.
Science Significance
The transition to Arletta Pharma highlights fifteen years of foundational scientific work addressing the complex neurobiological and physiological mechanisms underlying female sexual disorders, an area historically marked by limited therapeutic innovation. The company’s investigational therapy Lybrido™ showcases an innovative dual-action mechanism, combining a sublingual testosterone coating with a sildenafil-based inner core engineered for delayed-immediate release. This design synchronizes hormonal and vascular components of sexual response, improving genital blood flow, arousal responsivity, and sexual motivation within a 3–6 hour therapeutic window. The ongoing CDU Phase II study employs advanced doppler-based imaging to quantify clitoral hemodynamics, representing a scientifically rigorous method for evaluating treatment efficacy in a sensitive and under-researched domain.
Regulatory Significance
Arletta Pharma’s rebranding aligns strategically with its objective of securing eventual regulatory approval in Europe. The company’s active preparation for the ALETTA pivotal study across 20 research sites in five countries underscores its transition from exploratory to registrational development. As FSIAD is recognized under DSM-5 and ICD-11 (codes HA00/HA01.0), Lybrido™ directly targets a clinically validated and medically codified disorder. With more than 20 Phase I and Phase IIa studies, and large-scale Phase IIb trials across 17 U.S. sites, Arletta Pharma is building a robust evidence package in line with international regulatory expectations. The company’s movement into late-stage clinical execution signals increasing regulatory readiness and strengthens its global development footprint.
Business Significance
Advertisement
The rebrand to Arletta Pharma Solutions serves as a strategic business inflection point, communicating maturity, scientific credibility and readiness for expansion. As the organization advances toward pivotal trials, the strengthened brand identity supports investor engagement, partnership-building, and preparation for large-scale clinical operations. Lybrido™ represents a potential first-in-class therapy for FSIAD/HSDD, two significant yet underserved conditions that affect relationship stability, emotional wellbeing and quality of life for millions of women. With the rebrand anchored in symbolism of transformation, Arletta Pharma positions itself as a leader in women’s health innovation, leveraging extensive clinical data to enter a market with substantial unmet need and limited pharmaceutical competition.
Patients’ Significance
For women living with FSIAD/HSDD—conditions associated with distress, relationship strain, and profound reductions in emotional wellbeing—Arletta Pharma’s work represents a meaningful step toward improved, personalized care. By developing an on-demand, non-daily therapeutic option, Lybrido™ addresses patient preferences and provides an alternative to existing treatments that may be less targeted or effective. The therapy’s dual-action profile acknowledges the complex interplay of psychological, hormonal and physiological components of female sexual response. As Arletta prepares high-quality late-stage studies, patients stand to benefit from treatments that respect the specificity and sensitivity of female sexual health, with the potential to restore confidence, intimacy and wellbeing.
Policy Significance
Arletta Pharma’s focus aligns with broader health-policy shifts toward women’s health equity, recognition of historically underfunded therapeutic areas, and the need for evidence-based interventions that address conditions affecting mental, emotional and relational quality of life. As FSIAD/HSDD are officially recognized in DSM-5 and WHO’s ICD-11, the development of targeted therapies supports global health objectives to reduce stigma and enhance access to validated treatments for women’s sexual health. The company’s investment in rigorous imaging techniques, large-scale European trials and scientifically grounded formulations reflects evolving policy priorities encouraging sex-specific research, inclusive clinical design, and innovation in areas long neglected by mainstream pharmaceutical development.
Arletta Pharma Solutions’ rebranding marks an important milestone in the evolution of a company dedicated to transforming care for women with FSIAD and HSDD. With its science-driven identity, active Phase II program, and preparations for pivotal clinical studies, Arletta is positioned to redefine therapeutic options in a field where effective solutions have been scarce. As the organization advances its mission to deliver innovative, accessible treatments, its renewed identity symbolizes not only corporate transformation but also the broader commitment to elevating women’s health as a scientific and societal priority.
Source: Arletta Pharma Solutions press release
